Penumbra, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US70975L1070
USD
294.72
9.01 (3.15%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Penumbra, Inc. stock-summary
stock-summary
Penumbra, Inc.
Pharmaceuticals & Biotechnology
Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.
Company Coordinates stock-summary
Company Details
1 Penumbra , ALAMEDA CA : 94502-7676
stock-summary
Tel: 1 510 9952486
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 117 Schemes (61.78%)

Foreign Institutions

Held by 183 Foreign Institutions (11.11%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Adam Elsesser
Chairman of the Board, Chief Executive Officer
Dr. Arani Bose
Chief Innovator, Director
Mr. Harpreet Grewal
Independent Director
Mr. Don Kassing
Presiding Independent Director
Ms. Janet Leeds
Independent Director
Ms. Bridget O'Rourke
Independent Director
Ms. Surbhi Sarna
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
339 Million
(Quarterly Results - Jun 2025)
Net Profit:
45 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 11,138 Million (Small Cap)

stock-summary
P/E

84.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.32

stock-summary
Return on Equity

11.41%

stock-summary
Price to Book

8.61